Immorta Bio's SenoVax Shows Tumor Regression Across Multiple Cancer Types in Preclinical Studies
Key Insights
Immorta Bio (search)'s SenoVax, a first-in-class senolytic immunotherapy, demonstrated regression of brain, lung, skin, pancreas, and breast cancers in animal models by targeting senescent cells (search) that protect tumors from immune attack.
The therapy works by training the immune system to selectively eliminate senescent cells (search) through antibody and T cell responses, removing a key defense mechanism that shields cancer from immune destruction.
Preclinical data published in peer-reviewed literature with collaborators from UC San Diego, Georgetown University, and Cedars Sinai (search) validates the scientific approach of using longevity technologies to address cancer treatment.
Immorta Bio (search) Inc. has announced promising preclinical results for SenoVax, its lead senolytic immunotherapy product, showing tumor regression across multiple cancer types in animal models. The Miami-based longevity company presented data demonstrating the therapy's effectiveness against lung, breast, pancreatic, brain cancers, and melanoma (search) at recent scientific conferences.
Novel Mechanism Targets Cancer's Protective Shield
SenoVax represents the first senolytic immunotherapy designed to treat both cancer and aging by training the immune system to selectively eliminate senescent cells (search). These aged cells play a critical role in cancer progression by acting as a protective shield that prevents immune responses from attacking tumors.
"It has been widely demonstrated that senescent cells (search) play a critical role in initiating, promoting and protecting cancer," said Dr. Thomas Ichim, President and Chief Scientific Officer of Immorta Bio (search). "By amplifying the body's natural immunological activities to kill senescent cells, SenoVax induces regression of tumors."
The therapy works by removing this defense mechanism, making cancer cells susceptible to immune attack. According to the company, this approach addresses a fundamental challenge in cancer treatment by targeting the tumor microenvironment rather than just the cancer cells themselves.
Peer-Reviewed Validation and Collaborative Research
The scientific foundation for SenoVax has been established through collaborative research with leading academic institutions. Immorta Bio (search), working with the University of California San Diego, Georgetown University, Calidi Biosciences (search), and Cedars Sinai (search), published peer-reviewed data demonstrating that SenoVax kills cancer by inducing antibody and T cell responses that eliminate senescent cells (search).
The research has revealed multiple mechanisms of action for the therapy. T cell-mediated mechanisms have been documented in the peer-reviewed literature, while recent studies have also shown that natural killer cell activation plays a role in stimulating cancer destruction following SenoVax treatment.
Scientific Recognition and Conference Presentations
The company's research has gained recognition in the scientific community, with Immorta Bio (search) selected to present at the Clinical Immunology Symposium of the American Association of Immunologists Annual Meeting. The presentation, titled "Immunologically Mediated Senolysis," was featured alongside presentations from Pfizer and the University of Pittsburgh.
"Having been chosen to present our work on using the immune system to fight cancer and aging in such an esteemed panel is truly an honor," said Dr. Ichim.
Dr. Boris Reznik, Chairman and CEO of Immorta Bio (search), also presented the latest SenoVax findings at the LSX Investival Showcase, providing updates on the company's oncology program and discussing the cellular mechanisms by which the longevity therapeutic targets various cancers.
Strategic Development Approach
Immorta Bio (search) has positioned itself as a "scientific longevity company" focused on treating diseases of aging and treating aging as a disease. The company's development strategy involves applying longevity-associated technologies to address unmet medical needs with accelerated timelines.
"We are developing multiple programs focused on radical extension of human healthspan including our senolytic immunotherapy platform," said Dr. Reznik. "Our development strategy is to apply longevity-associated technologies to address unmet medical needs that can provide answers in months not decades."
The validation of SenoVax's scientific approach through peer-reviewed publications and presentations at prestigious conferences represents a significant milestone for the emerging field of senolytic immunotherapy, potentially opening new avenues for cancer treatment that leverage the body's natural aging processes.